Stopping Disease in its Tracks by blocking myeloid cell migration
New Biology. Broad potential. Patients First.
Clinical-Stage company developing therapies for I&I
New Adhesion Checkpoint Discovered
We are focused on development of novel therapies for patients with immune inflammatory indications. Our main program is based on the discovery of a novel adhesion checkpoint, that controls the ability of certain immune cells to reach inflamed tissues.
Preventing Monocytes and Neutrophils from Entering Inflamed Tissues
Our lead clinical-stage candidate, IW-601, is a proprietary monoclonal antibody that is engineered to specifically prevent monocytes and neutrophils from entering inflamed tissues. IW-601 is designed to offer a novel and differentiated approach in the landscape of current anti-inflammatory agents.
Potential for Highly Prevalent and Rare Inflammatory Indications
Following demonstration of disease-modifying activity in models of Multiple Sclerosis, Rheumatoid Arthritis, Inflammatory Bowel Disease and Metabolic dysfunction-associated steatohepatitis (MASH), IW-601 was studied in the POINTGUARD Phase 1 clinical trial. The trial met all primary and secondary endpoints and demonstrated positive safety, pharmacokinetics and mechanistic validation.
Ph1b data in 1H2027 & Ph2 launch in 2H2027 expected to drive significant upside.
